Ovarian Cancer Diagnostics
Published on Jun 08 2010, in the categories: Disease stages, Ovarian cancer
A new ovarian cancer diagnostic tool, which, according to studies may help determine the risk of malignancy or benign pelvic mass, is now available in Europe. This simple blood test can provide valuable information on the assessment of epithelial ovarian cancer, the most lethal gynecological cancer. It is an important immunological test, which runs on the system developed by Abbott ARCHITECT, HE4 was the first automated test available worldwide.
Research has shown that this new ovarian cancer diagnostic device, used together with other tests, such as CA125 assessment can help measure the risk of epithelial ovarian cancer, both before menopause, and postmenopausal women presenting in the pelvic mass. According to the International Agency for Research on Cancer, five-year survival rate of patients with cancer is of 46 percent.
However, when the disease is diagnosed early, this rate increases to 94 percent. Ovarian cancer is the leading cause of death after contracting a gynecological cancer and the fifth cause of death from cancer in females. Ovarian cancer affects one in 72 women, this disease represents 31 percent of cancers of the female genitalia. After menopause, ovarian cancer risk increases considerably.
The ability of this test to help doctors to establish whether it is benign or malignant pelvic mass is an important step both for patients and for professionals", said Michael Warmuth, vice president of Abbott Diagnostics. "ARCHITECT HE4 test comes in to help doctors determine the most appropriate treatment for patients," he completes.
In the new product development process, Abbott has signed a partnership agreement with Fujirebio Diagnostics Incorporated. The new tool is now available in several European countries, but in some countries in Asia and Latin America. Abbott recently sought the opinion of the U.S. Food and Drug Administration for marketing ARCHITECT HE4 test in the United States of America. Abbott Company provides medical services to global business activities which are dedicated to the discovery, development, manufacture and sale of medical products and pharmaceuticals. Company portfolio includes nutritional products, medical devices, diagnostic and hard. Abbott has over 72,000 employees and sells its products in over 130 countries.
Meanwhile, the company's Diagnostic Division (Abbott Diagnostics) is a world leader in in-vitro diagnostics and offers a wide range of systems, medical instruments and tests innovative units for hospitals, medical laboratories, blood bank storage, clinics and offices medical. With more than 69,000 institutional customers in over 100 countries, the department offers consumers products that provide automation, convenience, cost efficiency and flexibility. Abbott Diagnostics portfolio contains many unique products a significant technological development, including the first diagnostic test to detect HIV.
Research has shown that this new ovarian cancer diagnostic device, used together with other tests, such as CA125 assessment can help measure the risk of epithelial ovarian cancer, both before menopause, and postmenopausal women presenting in the pelvic mass. According to the International Agency for Research on Cancer, five-year survival rate of patients with cancer is of 46 percent.
However, when the disease is diagnosed early, this rate increases to 94 percent. Ovarian cancer is the leading cause of death after contracting a gynecological cancer and the fifth cause of death from cancer in females. Ovarian cancer affects one in 72 women, this disease represents 31 percent of cancers of the female genitalia. After menopause, ovarian cancer risk increases considerably.
The ability of this test to help doctors to establish whether it is benign or malignant pelvic mass is an important step both for patients and for professionals", said Michael Warmuth, vice president of Abbott Diagnostics. "ARCHITECT HE4 test comes in to help doctors determine the most appropriate treatment for patients," he completes.
In the new product development process, Abbott has signed a partnership agreement with Fujirebio Diagnostics Incorporated. The new tool is now available in several European countries, but in some countries in Asia and Latin America. Abbott recently sought the opinion of the U.S. Food and Drug Administration for marketing ARCHITECT HE4 test in the United States of America. Abbott Company provides medical services to global business activities which are dedicated to the discovery, development, manufacture and sale of medical products and pharmaceuticals. Company portfolio includes nutritional products, medical devices, diagnostic and hard. Abbott has over 72,000 employees and sells its products in over 130 countries.
Meanwhile, the company's Diagnostic Division (Abbott Diagnostics) is a world leader in in-vitro diagnostics and offers a wide range of systems, medical instruments and tests innovative units for hospitals, medical laboratories, blood bank storage, clinics and offices medical. With more than 69,000 institutional customers in over 100 countries, the department offers consumers products that provide automation, convenience, cost efficiency and flexibility. Abbott Diagnostics portfolio contains many unique products a significant technological development, including the first diagnostic test to detect HIV.
If you liked this post, subscribe to our blog by filling your e-mail address below:
Want to add something? Post your comments